Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
05 10 2023
Historique:
received: 05 05 2023
revised: 17 07 2023
accepted: 08 08 2023
medline: 6 10 2023
pubmed: 15 9 2023
entrez: 15 9 2023
Statut: ppublish

Résumé

Small-molecule chemical "probes" complement the use of molecular biology techniques to explore, validate, and generate hypotheses on the function of proteins in diseases such as cancer. Unfortunately, the poor selection and use of small-molecule reagents can lead to incorrect conclusions. Here, we illustrate examples of poor chemical tools and suggest best practices for the selection, validation, and use of high-quality chemical probes in cancer research. We also note the complexity associated with tools for novel drug modalities, exemplified by protein degraders, and provide advice and resources to facilitate the independent identification of appropriate small-molecule probes by researchers. Validation of biological targets and pathways will be aided by a shared understanding of the criteria of potency, selectivity, and target engagement associated with small-molecule reagents ("chemical probes") that enable that work. Interdisciplinary collaboration between cancer biologists, medicinal chemists, and chemical biologists and the awareness of available resources will reduce misleading data generation and interpretation, strengthen data robustness, and improve productivity in academic and industrial research.

Identifiants

pubmed: 37712569
pii: 729075
doi: 10.1158/2159-8290.CD-23-0536
doi:

Substances chimiques

Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2150-2165

Subventions

Organisme : Cancer Research UK
ID : 22897
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C35696/A23187
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212969/Z/18/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C309/A11566
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C309/A31322
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C309/A27413
Pays : United Kingdom

Informations de copyright

©2023 American Association for Cancer Research.

Auteurs

Mary M Mader (MM)

Indiana Biosciences Research Institute, Indianapolis, Indiana.
Chemistry in Cancer Research (CICR) Working Group of the American Association for Cancer Research, Philadelphia, Pennsylvania.

Joachim Rudolph (J)

Chemistry in Cancer Research (CICR) Working Group of the American Association for Cancer Research, Philadelphia, Pennsylvania.
Genentech, Inc., South San Francisco, California.

Ingo V Hartung (IV)

Chemistry in Cancer Research (CICR) Working Group of the American Association for Cancer Research, Philadelphia, Pennsylvania.
Merck Healthcare KGaA, Darmstadt, Germany.

David Uehling (D)

Chemistry in Cancer Research (CICR) Working Group of the American Association for Cancer Research, Philadelphia, Pennsylvania.
Ontario Institute for Cancer Research, Toronto, Canada.

Paul Workman (P)

Chemistry in Cancer Research (CICR) Working Group of the American Association for Cancer Research, Philadelphia, Pennsylvania.
Centre for Cancer Drug Discovery, The Institute of Cancer Research (London), Sutton, United Kingdom.
Chemical Probes Portal (www.chemicalprobes.org).

William Zuercher (W)

Chemistry in Cancer Research (CICR) Working Group of the American Association for Cancer Research, Philadelphia, Pennsylvania.
F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH